Tokyo, Japan, Japan · Est. 1921 · 47,000 employees
Otsuka Pharmaceutical is a diversified pharmaceutical company developing and marketing medications across psychiatry, oncology, and other therapeutic areas globally.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
By Phase
19 drugs in development
By Therapeutic Area
top 6
R&D Momentum
66/100
Pipeline Velocity
39/100
Trial Completion Rate
90/100
Pipeline Concentration
11/100
Pipeline Freshness
71/100
Strategic Signals
Activity
Last 14 days
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia
International, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria
A Phase 1/2, First-In-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Details
Company Overview
—
Mkt Cap
$25.2M
Revenue
$2.2M
Cash
Therapeutic Focus
Pipeline
Regulatory
Bacteriostatic Water For Injection In Plastic Container — STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
Application NDA019869 (NDA)
Dextrose 10% In Plastic Container — DEXTROSE 50% IN PLASTIC CONTAINER
Application NDA019894 (NDA)
Dextrose 10% In Plastic Container — DEXTROSE 50% IN PLASTIC CONTAINER
Application NDA020047 (NDA)
Dextrose 10% In Plastic Container — DEXTROSE 5% IN PLASTIC CONTAINER
Application NDA020179 (NDA)
Dextrose 10% In Plastic Container — DEXTROSE 5% IN PLASTIC CONTAINER
Application NDA019971 (NDA)
Dextrose 10% In Plastic Container — DEXTROSE 25%
Application NDA019445 (NDA)
Pletal — PLETAL
Application NDA020863 (NDA)
Abilify — ABILIFY
Application NDA021436 (NDA)
Abilify — ABILIFY
Application NDA021713 (NDA)
Abilify — ABILIFY
Application NDA021866 (NDA)
Abilify — ABILIFY
Application NDA021729 (NDA)
Samsca — SAMSCA
Application NDA022275 (NDA)
Abilify — ABILIFY MAINTENA KIT
Application NDA202971 (NDA)
Rexulti — REXULTI
Application NDA205422 (NDA)
Abilify — ABILIFY MYCITE KIT
Application NDA207202 (NDA)
Samsca — JYNARQUE
Application NDA204441 (NDA)
Abilify — ABILIFY ASIMTUFII
Application NDA217006 (NDA)
Abilify — OPIPZA
Application NDA216655 (NDA)
VOYXACT — VOYXACT
Application BLA761434 (BLA)
Abilify — MEZOFY
Application NDA211448 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)